For estrogen receptor positive breast cancer, aromatase inhibitor treatment (AIT) is used as a single agent in postmenopausal women and in premenopausal women in combination with ovarian function suppression or ablation [1, 2]. Here, CYP19A1 is linked to breast cancer.